Bisphosphonate-associated osteonecrosis of the jaw is linked to suppressed TGFβ1-signaling and increased Galectin-3 expression: A histological study on biopsies

Journal of Translational Medicine

Kerstin Amann³  Friedrich W Neukam²  Karl A Schlegel²  Phillip Stockmann²  Emeka Nkenke²  Arndt Guentsch⁴  Peter Hyckel¹  Falk Wehrhan² 

[1] Department of Plastic Surgery/St. Georg-Hospital Eisenach University of Jena, Germany;Department of Oral and Maxillofacial Surgery University of Erlangen-Nuremberg, Germany;Institute of Pathology University of Erlangen-Nuremberg, Germany;Department of Conservative Dentistry University of Jena, Germany

关键词: oral surgery;    galectin-3;    transforming growth factor beta 1;    oral soft tissue;    BRONJ;   

Others  :  1207916
DOI  :  10.1186/1479-5876-9-102

 received in 2010-10-07, accepted in 2011-07-04,  发布年份 2011

【 摘 要 】

Background

Bisphosphonate associated osteonecrosis of the jaw (BRONJ) implies an impairment in oral hard- and soft tissue repair. An understanding of the signal transduction alterations involved can inform therapeutic strategies. Transforming growth factor β1 (TGFβ1) is a critical regulator of tissue repair; galectin-3 mediates tissue differentiation and specifically modulates periodontopathic bacterial infection. The aim of this study was to compare the expression of TGFβ1-related signaling molecules and Galectin-3 in BRONJ-affected and healthy mucosal tissues. To discriminate between BRONJ-specific impairments in TGFβ1 signaling and secondary inflammatory changes, the results were compared to the expression of TGFβ1 and Galectin-3 in mucosal tissues with osteoradionecrosis.

Methods

Oral mucosal tissue samples with histologically-confirmed BRONJ (n = 20), osteoradionecrosis (n = 20), and no lesions (normal, n = 20) were processed for immunohistochemistry. Automated staining with an alkaline phosphatase-anti-alkaline phosphatase kit was used to detect TGFβ1, Smad-2/3, Smad-7, and Galectin-3. We semiquantitatively assessed the ratio of stained cells/total number of cells (labeling index, Bonferroni-adjustment).

Results

TGFβ1 and Smad-2/3 were significantly decreased (p < 0.032 and p(0.028, respectively) in the BRONJ samples and significantly increased (p < 0.04 and p <0.043, respectively) in the osteoradionecrosis samples compared to normal tissue. Smad-7 was significantly increased (p < 0.031) in the BRONJ group and significantly decreased (p < 0.026) in the osteoradionecrosis group. Galectin-3 staining was significantly (p < 0.025) increased in both the BRONJ and the osteoradionecrosis (p < 0.038) groups compared to the normal tissue group. However, Galectin-3 expression was significantly higher in the BRONJ samples than in the osteoradionecrosis samples (p < 0.044).

Conclusion

Our results showed that disrupted TGFβ1 signaling was associated with delayed periodontal repair in BRONJ samples. The findings also indicated that impairments in TGFβ1-signaling were different in BRONJ compared to osteoradionecrosis. BRONJ appeared to be associated with increased terminal osseous differentiation and decreased soft tissue proliferation. The increase in Galectin-3 reflected the increase in osseous differentiation of mucoperiosteal progenitors, and this might explain the inflammatory anergy observed in BRONJ-affected soft tissues. The results substantiated the clinical success of treating BRONJ with sequestrectomy, followed by strict mucosa closure. BRONJ can be further elucidated by investigating the specific intraoral osteoimmunologic status.

【 授权许可】

   
2011 Wehrhan et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Reid IR: Osteonecrosis of the jaw: who gets it, and why? Bone 2009, 44:4-10.
• [2]Hansen T, Kunkel M, Kirkpatrick CJ, Weber A: Actinomyces in infected osteoradionecrosis--underestimated? Hum Pathol 2006, 37:61-67.
• [3]Wehrhan F, Hyckel P, Ries J, Stockmann P, Nkenke E, Schlegel K, Neukam F, Amann K: Expression of Msx-1 is suppressed in bisphosphonate associated osteonecrosis related jaw tissue -etiopathology considerations respecting jaw developmental biology-related unique features. Journal of Translational Medicine 2010., 13/8(96)
• [4]Reddy GT, Kumar TM, Veena : Formulation and evaluation of Alendronate Sodium gel for the treatment of bone resorptive lesions in Periodontitis. Drug Deliv 2005, 12:217-222.
• [5]Levin L, Laviv A, Schwartz-Arad D: Denture-related osteonecrosis of the maxilla associated with oral bisphosphonate treatment. J Am Dent Assoc 2007, 138:1218-1220.
• [6]Duque G, Rivas D: Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells. J Bone Miner Res 2007, 22:1603-1611.
• [7]Simon MJ, Niehoff P, Kimmig B, Wiltfang J, Acil Y: Expression profile and synthesis of different collagen types I, II, III, and V of human gingival fibroblasts, osteoblasts, and SaOS-2 cells after bisphosphonate treatment. Clin Oral Investig 2009, 14(1):51-8.
• [8]Flanders KC: Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 2004, 85:47-64.
• [9]Border WA, Noble NA, Yamamoto T, Harper JR, Yamaguchi Y, Pierschbacher MD, Ruoslahti E: Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 1992, 360:361-364.
• [10]Kopecki Z, Luchetti MM, Adams DH, Strudwick X, Mantamadiotis T, Stoppacciaro A, Gabrielli A, Ramsay RG, Cowin AJ: Collagen loss and impaired wound healing is associated with c-Myb deficiency. J Pathol 2007, 211:351-361.
• [11]Gold LI, Sung JJ, Siebert JW, Longaker MT: Type I (RI) and type II (RII) receptors for transforming growth factor-beta isoforms are expressed subsequent to transforming growth factor-beta ligands during excisional wound repair. AmJPathol 1997, 150:209-222.
• [12]Lehner B, Bauer J, Rodel F, Grabenbauer G, Neukam FW, Schultze-Mosgau S: Radiation-induced impairment of osseous healing with vascularized bone transfer: experimental model using a pedicled tibia flap in rat. Int J Oral Maxillofac Surg 2004, 33:486-492.
• [13]Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, Liu FT, Hughes J, Sethi T: Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008, 172:288-298.
• [14]Ortega N, Behonick DJ, Colnot C, Cooper DN, Werb Z: Galectin-3 is a downstream regulator of matrix metalloproteinase-9 function during endochondral bone formation. Mol Biol Cell 2005, 16:3028-3039.
• [15]Plzak J, Smetana K, Chovanec M, Betka J: Glycobiology of head and neck squamous epithelia and carcinomas. ORL J Otorhinolaryngol Relat Spec 2005, 67:61-69.
• [16]Kato T, Uzawa A, Ishihara K: Inhibitory effect of galectin-3 on the cytokine-inducing activity of periodontopathic Aggregatibacter actinomycetemcomitans endotoxin in splenocytes derived from mice. FEMS Immunol Med Microbiol 2009, 57(1):40-5.
• [17]Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, et al.: Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22:1479-1491.
• [18]Stockmann P, Vairaktaris E, Wehrhan F, Seiss M, Schwarz S, Spriewald B, Neukam FW, Nkenke E: Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer 2009, 18(4):449-60.
• [19]Weibel ER: Measuring through the microscope: development and evolution of stereological methods. J Microsc 1989, 155:393-403.
• [20]Schultze-Mosgau S, Kopp J, Thorwarth M, Rodel F, Melnychenko I, Grabenbauer GG, Amann K, Wehrhan F: Plasminogen activator inhibitor-I-related regulation of procollagen I (alpha(1) and alpha(2)) by antitransforming growth factor-beta(1) treatment during radiation-impaired wound healing. IntJRadiatOncolBiolPhys 2006, 64:280-288.
• [21]Wehrhan F, Grabenbauer GG, Rodel F, Amann K, Schultze-Mosgau S: Exogenous Modulation of TGF-beta(1) Influences TGF-betaR-III-Associated Vascularization during Wound Healing in Irradiated Tissue 1. StrahlentherOnkol 2004, 180:526-533.
• [22]Wehrhan F, Rodel F, Grabenbauer GG, Amann K, Bruckl W, Schultze-Mosgau S: Transforming growth factor beta 1 dependent regulation of Tenascin-C in radiation impaired wound healing. RadiotherOncol 2004, 72:297-303.
• [23]Schultze-Mosgau S, Blaese MA, Grabenbauer G, Wehrhan F, Kopp J, Amann K, Rodemann HP, Rodel F: Smad-3 and Smad-7 expression following anti-transforming growth factor beta 1 (TGFbeta(1))-treatment in irradiated rat tissue 1. RadiotherOncol 2004, 70:249-259.
• [24]Mohammadi M, Shokrgozar MA, Mofid R: Culture of human gingival fibroblasts on a biodegradable scaffold and evaluation of its effect on attached gingiva: a randomized, controlled pilot study. J Periodontol 2007, 78:1897-1903.
• [25]Lekic P, Rubbino I, Krasnoshtein F, Cheifetz S, McCulloch CA, Tenenbaum H: Bisphosphonate modulates proliferation and differentiation of rat periodontal ligament cells during wound healing. Anat Rec 1997, 247:329-340.
• [26]Fu L, Tang T, Miao Y, Zhang S, Qu Z, Dai K: Stimulation of osteogenic differentiation and inhibition of adipogenic differentiation in bone marrow stromal cells by alendronate via ERK and JNK activation. Bone 2008, 43:40-47.
• [27]Mercer N, Ahmed H, Etcheverry SB, Vasta GR, Cortizo AM: Regulation of advanced glycation end product (AGE) receptors and apoptosis by AGEs in osteoblast-like cells. Mol Cell Biochem 2007, 306:87-94.
• [28]Aubin JE, Liu F, Malaval L, Gupta AK: Osteoblast and chondroblast differentiation. Bone 1995, 17:77S-83S.
• [29]Philippe L, Simon AN, Jean-Pierre C, Brigitte B, Tommaso L, Jean-Pierre W, Rene R, Jean-Louis S, Jacky S: Bisphosphonate-associated osteonecrosis of the jaw: A key role of inflammation? Bone 2009, 45(5):843-52.